Summary of Major Modifications

The Technical Document on Minimum Required Performance Levels for Detection and Identification of Non-Threshold Substances has undergone a revision by WADA’s Laboratory Expert Group (LabEG).

The new version of the document, TD2017MRPL, includes the following main modifications:

1.0 Minimum Required Performance Levels (MRPL)

It has been clarified at the end of this section that since the metabolic and excretion patterns of Prohibited Substances may vary substantially with time after administration, it is important that Laboratories include in their analytical procedures relevant target analytes to ensure the detection of the Prohibited Substance as extensively as possible.

Table 1

In Table 1, MRPLs were added for:

1) **S0. Non-approved substances** (e.g. AOD9604): 2 ng/mL
2) **S1.2 Other Anabolic Agents**: 2 ng/mL
3) **S2.2. HIF Stabilizers**: 2 ng/mL
4) **S2.3 Gonadotropin Releasing Hormone (GnRH)**: 2 ng/mL
5) **S2.5 Growth Hormone (GH) Releasing Factors**:
   - GH-Releasing Hormone (GHRH) and its analogues: MRPL changed to 1 ng/mL
   - Addition of a new category for other Growth Factors: 2 ng/mL
6) **S4. Hormone and Metabolic Modulators**:
   - Meldonium: 200 ng/mL
   - Insulin: 50 pg/mL

Footnotes (b, e, f, g) have been added to clarify that some substances classified in the categories of Prohibited Substances included in Table 1 are considered Threshold Substances and, therefore, their determination and reporting is covered in the Technical Document on Decision Limits (TDDL).

A footnote (i) has been added to clarify that all Laboratories shall have analytical capacity to test for small peptides and that Testing Authorities should be aware that Testing for these substances may not be part of the Laboratory routine Analytical Testing menu.
4.0 Reporting of Non-Threshold Substances

It has been specified that higenamine should not be reported at levels below 10 ng/mL.

It has been specified that meldonium should not be reported at levels below 100 ng/mL.

The notes on detection and reporting of hydromorphone have been removed. This will be addressed in a future Technical Letter.

Footnotes 6 and 7 have been added at the end of the section to clarify the target analytes for application of the reporting limits specified for Non-Threshold Substances in classes S6, S7, S8, S9 and P2 and for salmeterol and higenamine, respectively.